Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$77.93 USD

77.93
3,220,670

-0.68 (-0.87%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $77.93 0.00 (0.00%) 6:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

What's in Store for Cerner (CERN) This Earnings Season?

by Zacks Equity Research

Cerner's (CERN) Q2 results are likely to show softer performance owing to declining revenues across core business segments.

    Zacks Equity Research

    What's in Store for AmerisourceBergen (ABC) in Q3 Earnings?

    by Zacks Equity Research

    AmerisourceBergen's (ABC) Q3 results are likely to be driven by its core Pharmaceutical Distribution business; a competitive industry is a headwind.

      Zacks Equity Research

      Will Edwards' (EW) Steady Overall Growth Drive Q2 Earnings?

      by Zacks Equity Research

      Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q2.

        Zacks Equity Research

        Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?

        by Zacks Equity Research

        Becton, Dickinson's (BDX) core BD Medical likely to register solid results in Q3; a possible decline in BD Life Sciences raises concern.

          Zacks Equity Research

          Can Business Services Aid athenahealth's (ATHN) Q2 Earnings?

          by Zacks Equity Research

          athenahealth's (ATHN) core Business Services unit is likely to drive growth in Q2; the company's focus on cloud-based services is encouraging.

            Zacks Equity Research

            Can Overall Growth Drive Align Technology (ALGN) Q2 Earnings?

            by Zacks Equity Research

            Align Technology (ALGN) likely to gain from strength in Invisalign space as well as Scanner and Service business in Q2.

              Zacks Equity Research

              Here's Why You Should Add Edwards Lifesciences (EW) Now

              by Zacks Equity Research

              We are upbeat about Edwards Lifesciences' (EW) strong transcatheter valve sales in the domestic market as well as overseas.

                Kevin Cook headshot

                Bear of the Day: Barrick Gold (ABX)

                by Kevin Cook

                Growth estimates were falling when gold was rising, thus not surprising to see them slip further

                  Sweta Killa headshot

                  Should iShares Morningstar Mid-Cap Growth ETF (JKH) Be on Your Investing Radar?

                  by Sweta Killa

                  Style Box ETF report for JKH

                    Kevin Cook headshot

                    How to Play the New Hawkish Fed

                    by Kevin Cook

                    If you understand what stock market players are afraid of, you can ride the market to higher gains this summer.

                      Zacks Equity Research

                      Why Is Edwards Lifesciences (EW) Up 1.5% Since Its Last Earnings Report?

                      by Zacks Equity Research

                      Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                        Zacks Equity Research

                        Edwards Lifesciences (EW) Q1 Earnings Beat, Revenues Miss

                        by Zacks Equity Research

                        Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q1.

                          Zacks Equity Research

                          Why Earnings Season Could Be Great for Edwards Lifesciences (EW)

                          by Zacks Equity Research

                          Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                            Zacks Equity Research

                            Edwards Lifesciences' (EW) THVT Likely to Drive Q1 Earnings

                            by Zacks Equity Research

                            Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies in Q1.

                              Zacks Equity Research

                              Can Steady Overall Growth Drive Align's (ALGN) Q1 Earnings?

                              by Zacks Equity Research

                              Align Technology (ALGN) is likely to gain from strength in the Invisalign space as well as Scanner and Service business in Q1.

                                Zacks Equity Research

                                Here's Why You Should Steer Clear of AmerisourceBergen Now

                                by Zacks Equity Research

                                AmerisourceBergen (ABC) continues to witness headwinds due to slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics.

                                  Zacks Equity Research

                                  Medical Instrument Stocks Head-to-Head: Abiomed vs. STERIS

                                  by Zacks Equity Research

                                  Here we take a look at the fundamentals of Abiomed (ABMD) and STERIS (STE) to determine which stock is a better pick in the Medical Instruments space.

                                    Zacks Equity Research

                                    Will Edwards' (EW) Growth in All Lines Drive Q1 Earnings?

                                    by Zacks Equity Research

                                    Edwards Lifesciences (EW) is expected to gain from strength in all the business segments and solid performance across all geographies.

                                      Zacks Equity Research

                                      Varian Medical (VAR) Launches Velocity 4.0, Shares Rise

                                      by Zacks Equity Research

                                      The introduction of Velocity 4.0 is in line with Varian Medical's (VAR) strategy to target the radiation-dosimetry market. The platform will help patients with liver malignancies.

                                        Zacks Equity Research

                                        Here's Why You Should Hold on to Varian Medical Stock Now

                                        by Zacks Equity Research

                                        Here we take a peek at Varian Medical's (VAR) performance to analyze why investors should hold on to this stock despite adversities.

                                          Zacks Equity Research

                                          Align Unveils Vivera Retainers for Deep Bite Correction

                                          by Zacks Equity Research

                                          Align (ALGN) hopes to taste greater clinical success in the orthodontic space with Vivera Retainers' integration into Precision Bite Ramps, which are part of the company's Invisalign G5.

                                            Zacks Equity Research

                                            Walgreens Boots' Retail Business Solid Amid Several Concerns

                                            by Zacks Equity Research

                                            Walgreens Boots (WBA) progresses with consistent sales rise in the Retail Pharmacy International business. Moreover, the stock grows on strategic alliances.

                                              Zacks Equity Research

                                              Haemonetics' Plasma Tool Enhancement Gets 510(K) Clearance

                                              by Zacks Equity Research

                                              Haemonetics (HAE) witnesses steady growth in Plasma franchise, led by strong end-market demand for plasma-derived biopharmaceuticals.

                                                Zacks Equity Research

                                                Walgreens Boots (WBA) Beats on Earnings in Q2, Lifts View

                                                by Zacks Equity Research

                                                Walgreens Boots (WBA) witnesses revenue growth across all three segments in Q2. A solid guidance instills investor confidence in the stock.

                                                  Zacks Equity Research

                                                  DexCom (DXCM) Gets FDA Approval for G6 CGM Monitoring System

                                                  by Zacks Equity Research

                                                  DexCom (DXCM) is a leading player in the global CGM markets.